Design of Retroviral Vectors and Helper Cells for Gene Therapy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
During the past decade, gene therapy has been applied to the treatment of disease in hundreds of clinical trials. Various tools have been developed to deliver genes into human cells; among them, genetically engineered retroviruses are currently the most popular tool for gene delivery. Most of the systems contain vectors that are capable of accommodating genes of interest and helper cells that can provide the viral structural proteins and enzymes to allow for the generation of vector-containing infectious viral particles. Retroviridae is a family of retroviruses that differs in nucleotide and amino acid sequence, genome structure, pathogenicity, and host range. This diversity provides opportunities to use viruses with different biological characteristics to develop different therapeutic applications. Currently, a variety of retroviruses that provide distinct advantages for gene delivery has been modified and used in clinical trials. In this review, the genome structures of oncoviruses, lentiviruses, and spumaviruses are reviewed and examples of vectors derived from these viruses are described. As with any delivery tool, the efficiency, the ability to target certain tissue or cell type, the expression of the gene of interest, and the safety of retroviral-based systems are important for successful application of gene therapy. Significant efforts have been dedicated to these areas of research in recent years. Various modifications have been made to retroviral-based vectors and helper cells to alter gene expression, target delivery, improve viral titers, and increase safety. The principles and design of these modifications are discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Lentivirus-based vectors were developed in part because they could be used to deliver genes into nondividing cells (Naldini et al., 1996; Blomer et al., 1997).”
Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., & Moen, R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.4.1125 · Cited by 532 · cited 1×
“Replication-competent MLV has been shown to cause lymphomas in primates used in gene therapy experiments (Donahue et al., 1992; Vanin et al., 1994; Purcell et al., 1996).”
Cited by
Converging Technologies for Improving Human Performance
(2003) · Springer eBooks · doi:10.1007/978-94-017-0359-8 · Cited by 794
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
“Among them, the most popular tools for gene delivery are genetically engineered retroviruses [33].”
Lundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G
Delviks-Frankenberry, K. A., Ackerman, D., Timberlake, N. D., Hamscher, M., Nikolaitchik, O. A., Hu, W.-S., Torbett, B. E., & Pathak, V. K. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2019.10.024 · Cited by 21
Self-citation
Metadata
- Authors
- Hu, W.-S., & Pathak, V. K.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 52
- Issue
- 4
- Pages
- 493-511
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2130699680
- Cited by
- 126
- References
- 3
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of Retroviral Vectors and Helper Cells for Gene Therapy. https://app.cochat.ai/papers/10.1016/s0031-6997(24)01467-4
- The paper
- Hu, W.-S., & Pathak, V. K. (2000). Design of Retroviral Vectors and Helper Cells for Gene Therapy. Pharmacological Reviews. https://doi.org/10.1016/s0031-6997(24)01467-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.